top of page

2022 Rome Action Plan on Paediatric HIV & TB

Stellenbosch University

TB DIAGNOSTICS

Stellenbosch University and FIND commit to:

170. Incorporate the development of paediatric specimen banks/repositories, including non-sputum sample types, into studies to support faster clinical evaluation of new TB diagnostics and ensure open access to academic groups and manufacturers.

171. Stellenbosch University also commits to evaluate and validate CAD for TB in children in collaboration with other global partners.

Updates

 - 

HIV MEDICINES FOR CHILDREN

Stellenbosch University commits to:

228. Complete investigation of DTG dispersible tablets in neonates by early 2024 with interim results by early 2024 and undertake investigation of DTG dissolvable oral film in neonates by the end of 2024, with support from UNITAID.

229. Collaborate with other GAP-f partners and pharmaceutical companies, to design and set up a platform to enable rapid investigation of neonatal PK of new antiretrovirals as well as key antibiotics and antivirals for inclusion in AHD package.

Updates

 - 

TB TREATMENT for CHILDREN, PREGNANT, POST-PARTUM AND BREASTFEEDING WOMEN

Stellenbosch University commits to:

372. Completing the TB CHAMP Trial studying TPT in children and adults who are household contacts of people with MDR-TB.

373. Study the use of 3HP using novel formulation in children below 2 years contacts of people with TB and disseminating data during 2023.

374. Study taste-masked novel dispersible formulations of Moxifloxicin and Linezolid in children to inform commercial developed.

375. Study Pretomanid in girls, through the IMPAACT network.

376. Evaluate the short HPMZ regimen (also called the Study 31 regimen) for PK, safety, tolerability and acceptability in children < 12 years with DS-TB, through the TBTC network.

377. Collaborate with WHO and University College London on data collection and curation

Updates

 - 

bottom of page